BSETrident Texofab LtdHighNeutral
Announced Sat, 30 May · 19:49 IST

Financial Result for Quarter and Year ended 31.03.2026

Revenue DeclinePat Growth 25pctPat NegativeResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-6.8%1-day move
₹43.51
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-6.8-6.5-10.6-11.9-17.0-15.4-9.2-15.7
Up moveDown movePending
AI summary

Trident Texofab Limited reported total income of ₹11,802.25 lakhs for FY2026, down from ₹12,205.62 lakhs in FY2025, representing a revenue decline of approximately 3.3%. The company achieved a significant turnaround, reporting profit after tax of ₹251.01 lakhs compared to a net loss of ₹191.47 lakhs in the previous year. Basic and diluted earnings per share improved from ₹-1.30 to ₹2.09. The statutory auditor, Shah Kailash & Associates LLP, issued an unmodified (clean) opinion on the financial results, and the CFO confirmed this in a declaration. The board meeting was held on May 30, 2026.

Likely market impact

The stock appears to have returned to profitability after a loss-making FY2025, which is a positive signal for shareholders. However, the top-line decline of ~3.3% may raise concerns about revenue growth. The clean audit opinion provides assurance on financial statement reliability.